Wellcome leap

This article originally appeared on Unlimited Hangout.

The world’s richest medical study organization, the Wellcome Trust, has teamed up with a pair of former DARPA directors who improved Silicon Valley’s skunkworks to usher in an age of nightmarish surveillance, including for babies as young as 3 month old. Their agenda can only advance if we allow it.

A UK nonprofit with ties to world-wide decay throughout the COVID-1 9 crisis as well as historical and current ties to the UK eugenics move launched a world-wide health-focused DARPA equivalent last year. The move croaked largely unnoticed by both mainstream and independent media.

The Wellcome Trust, which has arguably been second only to Bill Gates in its ability to influence events during the COVID-1 9 crisis and vaccination campaign, propelled its own world equivalent of the Pentagon’s secretive research agency last year, officially to combat the “most pressing health challenges of our time.”

Though first designed of in 2018, this particular Wellcome Trust initiative was spun off from the Trust last May with $300 million in initial funding. It instantly enticed two onetime DARPA executives, who had previously served in the upper echelons of Silicon Valley, to manage and plan its portfolio of projects.

This world-wide state DARPA, known as Wellcome Leap, seeks to achieve “breakthrough scientific and technological solutions” by or before 2030, with a focus on “complex world-wide health challenges.” The Wellcome Trust is open about how Wellcome Leap will apply the approaches of Silicon Valley and venture capital firms to the health and life science sector.

Unsurprisingly, their three current programs are poised to develop incredibly invasive tech-focused, and in some cases overtly transhumanist, medical engineerings, including a programme designed exclusively focused on using artificial intelligence( AI ), mobile sensors, and wearable brain-mapping tech “for childrens” three years old and younger.

This Unlimited Hangout investigation explores is not simply the four current programs of Wellcome Leap but also the people behind it. The arising situation is of an improbably ominous assignment that constitutes not only a great threat to current culture but to the future of humanity itself. An upcoming Unlimited Hangout investigation will examine the history of the Wellcome Trust along with its role in recent and current events.

Leap’s Leadership: Merging Man and Machine for the Military and Silicon Valley

The intentions of the Wellcome Leap are made clear by the woman chosen to lead it, former director of the Pentagon’s DARPA, Regina Dugan. Dugan began her job at DARPA in 1996; she passed a counterterrorism task force in 1999 before leaving DARPA about a year later.

After departing DARPA, she cofounded her own venture capital firm, Dugan Ventures, and then became special adviser to the US Army’s vice chief of staff from 2001 to 2003, which coincides with the invasions of Afghanistan and Iraq. In 2005, she caused a defense-focused tech conglomerate called RedXDefense, which contracts with the military and specifically for DARPA.

In 2009, under the Obama administration, Dugan was appointed director of DARPA by Defense Secretary Robert Gates. Much was induced over her being the first female conductor of the agency, but she is best retained at the agency for her so-called “Special Forces” approach to innovation. During her term, she formed DARPA’s now defunct Transformational Convergence Technology Office, which focused on social networks, synthetic biology, and machine intelligence.

Many of the topics previously to be organized by that power are now overseen by DARPA’s Biological Engineering Office, which was created in 2014 and focuses on everything “from programmable microbes to human-machine symbiosis.” The Biological Technologies Office, like Wellcome Leap, prosecutes a mixture of “health-focused” biotechnology programs and transhumanist endeavors.

Right before leaving the top role at DARPA, Dugan greenlighted the agency’s initial investments in mRNA vaccine technology, which led to DARPA’s investments in Pfizer and Moderna shortly after. The DARPA scientist who lobbied Dugan to back the program, Dan Wattendorf , now acts as the director of Innovative Technology Solutions at the Bill& Melinda Gates Foundation.

While Dugan’s efforts at DARPA are remembered foolishly by those in the national-security state, and likewise by those working in Silicon Valley, Dugan was investigated for conflicts of interest during her era as DARPA’s director, as her firm RedXDefense acquired millions in Department of Defense contracts during her tenure.

Though she had recused herself from any formal role at the company while conducting DARPA, she continued to hold a significant fiscal stake in the company, and a military investigation later felt she had transgressed moralities regulates to a significant degree.

Instead of being held accountable in any way, Dugan went on to become a top executive at Google, where she was brought on to manage Google’s Advanced Technology and Concoction Group( ATAP ), which it had spun out of Motorola Mobility after Google’s acquisition of that corporation in 2012. Google’s ATAP was modeled after DARPA and hired other ex-DARPA officials besides Dugan.

At Google, Dugan oversaw several programmes, including which are currently being the basis of Google’s “augmented reality” business, then known as Project Tango, as well as “smart” clothing in which multitouch sensors were entwine into textiles. Another projection that Dugan preceded involved the use of a “digital tattoo” to open smartphones. Perhaps most controversially, Dugan was also behind the process of drafting a “digital authentication pill.”

According to Dugan, when the pill is immersed, “your entire body becomes your authentication token.” Dugan framed the pill and many of her other efforts at Google as working to fix “the mechanical discrepancy between humans and electronics” by producing engineering that coalesces the human body with machines to diversifying degrees.

While serving in this capacity at Google, Dugan chaired a board at the 2013 Clinton Global Initiative called “Game-Changers in Technology” and attended the 2015 Bilderberg meeting where AI was a central topic of discussion.

In 2016, Dugan left Google for Facebook where she was chosen to be the first head of Facebook’s own DARP-Aequivalent research agency, then known as Building 8. DARPA’s ties to the causes of Facebook were discussed in a recent Unlimited Hangout report.

Under Dugan, Building 8 invested heavily in brain-machine interface technology, which has since induced the company’s “neural wearable” wristbands that claim to be able to anticipate movements of the handwriting and fingers from psyche signals alone. Facebook showcased prototypes of the project earlier this year.

Dugan left Facebook merely eighteen months after joining Building 8, announcing her designs “to focus on building and conducting a brand-new struggle, ” which was apparently a reference to Wellcome Leap. Dugan later said it was as if she had been training courses for her capacity at Wellcome Leap ever since recruit the workforce, framing it as the spire of her career.

When questioned in an interview earlier this year who the customer of Wellcome Leap are, Dugan yielded a long-winded answer but essentially responded that the project suffices the biotech and pharmaceutical manufactures, international organisation such as the UN, and public-private partnerships.

In addition to her capacity at Wellcome, Dugan is also a member of the Council on Foreign Relations-sponsored taskforce on US Technology and Innovation policy, which was formed in 2019. Other members include LinkedIn’s Reid Hoffman, McKinsey Institute Global Chairman James Manyika, former head of Google Eric Schmidt and President Biden’s controversial top science adviser Eric Lander.

The other exec at Wellcome Leap, chief operating officer Ken Gabriel, has a background closely confined to Dugan’s. Gabriel, like Dugan, is a onetime curriculum overseer at DARPA, where he produced the agency’s microelectromechanical organizations( MEMS) research from 1992 to 1996.

He acted as deputy managing director of DARPA from 1995 to 1996 and became director of the Electronics Technology Office from 1996 to 1997, where he was reportedly responsible for about half of all federal electronics-technology speculations. At DARPA, Gabriel worked closely with the FBI and the CIA.

Ken Gabriel Ken Gabriel- COO of Wellcome Leap. Source: Wellcome Leap

Gabriel left DARPA for Carnegie Mellon University, where he was in charge of the Office for Security Engineering in the aftermath of September 11, 2001. That office was created after 9/11 specific to help meet the national-security needs of the federal government, according to Carnegie Mellon’s announcement of the program.

Around that same time, Gabriel became regarded as “the architect of the MEMS industry” due to his past work at DARPA and his founding of the MEMS-focused semiconductor company Akustica in 2002. He served as Akustica’s chairman and chief technology officer until 2009, at which period he returned to work at DARPA where he helped as the agency’s deputy director, operating directly under Regina Dugan.

In 2012, Gabriel followed Dugan to Google’s Advanced Technology and Products Group, which he was actually responsible for creating. According to Gabriel, Google cofounders Larry Page and Sergey Brin tasked Gabriel with creating “a private sector ground-up model of DARPA” out of Motorola Mobility. Regina Dugan was placed in charge, and Gabriel again sufficed as her deputy.

In 2013, Dugan and Gabriel co-wrote a piece for the Harvard Business Review about how DARPA’s “Special Forces” innovation approach could revolutionize both both the public and private sectors if more widely applied.

Gabriel left Google in 2014, well before Dugan, to serve as the president and CEO of Charles Stark Draper Laboratory, better known as Draper Labs, which develops “innovative technology solutions” for the national-security community, with particular attention paid to biomedical arrangements, intensity, and space technology. Gabriel held that position until he abruptly resigned in 2020 to co-lead Wellcome Leap with Dugan.

In addition to his role at Wellcome, Gabriel is also a World Economic Forum “technology pioneer” and on the board of directors of Galvani Bioelectronics, a joint venture of GlaxoSmithKline, which is intimately linked to the Wellcome Trust, and the Google subsidiary Verily.

Galvani focuses on the development of “bioelectronic medicines” that are related to “implant-based modulation of neural signals” in an overt approach by the pharmaceutical industry and Silicon Valley to normalize transhumanist “medicines.”

The longtime chairman of the board of Galvani, on which Gabriel acts, was Moncef Slaoui, who is heading the US COVID-1 9 vaccine exploitation and rationing platform Running Warp Speed. Slaoui was relieved of its own position at Galvani this past March over well-substantiated claims of sexual harassment.

Jeremy Farrar, Pandemic Narrative Manager

While Dugan and Gabriel ostensibly pass the clothe, Wellcome Leap is the brainchild of Jeremy Farrar and Mike Ferguson, who serve as its heads. Farrar is the director of the Wellcome Trust itself, and Ferguson is deputy chairman of the Trust’s board of governors.

Farrar has been chairman of the Wellcome Trust since 2013 and has been actively involved in critical decision making at the highest level globally since the opening up of the COVID crisis. He is likewise an agenda contributor to the World Economic Forum and cochaired the WEF’s Africa meeting in 2019.

Farrar’s Wellcome Trust is also a WEF strategic partner and cofounded the COVID Action Platform with the WEF. Farrar was more recently behind the creation of Wellcome’s COVID-Zero initiative, which is also held to the WEF.

Farrar has enclose its own initiative as “an opportunity for companies to advance the science which will eventually reduce business disruption.” Thus far it has persuasion titans of finance, including Mastercard and Citadel, to invest millions in research and development at parties favored by the Wellcome Trust.

Wellcome Trust Director Jeremy Farrar with NTI Co-Chairman Sam Nunn Wellcome Trust Director Jeremy Farrar with NTI Co-Chairman Sam Nunn, who is heading the 2001 Dark Winter exercise.

Source: NTI.com

Some of Wellcome’s contentious medical-research projects in Africa, as well as its ties to the UK eugenics campaign, were investigated in a December article published at Unlimited Hangout.

That report likewise explores the intimate relationships of Wellcome to the Oxford-AstraZeneca COVID-1 9 inoculation, the purpose of applying which has now been restricted or banned in several countries. As mentioned in the introduction, the Wellcome Trust itself is the victim of an upcoming Unlimited Hangout investigation( Portion 2 ).

Jeremy Farrar, who was born in Singapore in 1961, had previously been head of the Oxford University Clinical Research Unit in Ho Chi Minh City, beginning in 1998. During that time, he authored several epidemiological research papers. He claimed in a 2014 Financial Times article that his decision to move to Vietnam was due to his condescension for meeting auditoriums full of white men.

Southeast Asia was obviously a much less governed environment for someone in the medical-research industry wishing to indulge in groundbreaking research. Although based in Vietnam, Farrar was sent by Oxford to various locatings around the globe to study epidemics happening in real time.

In 2009, when swine flu was wreaking desolation in Mexico, Farrar jumped on a plane to dive right into the action, something he also did for subsequent world-wide outbreaks of Ebola, MERS, and avian flu.

Over the past year, many questions have arisen viewing exactly how much power Farrar holds over world-wide public health policy. Recently, the US president’s chief medical consultant, Anthony Fauci, was forced to release his emails and match from March and April 2020 at the requirements of the the Washington Post.

The liberated emails uncover what appears to be a high-level conspiracy by some of the top medical sovereignties in the US to falsely claim that COVID-1 9 could only have been of zoonotic descent, despite express to the contrary. The emails were heavily redacted as such emails frequently are, presumably to protect the information of the people involved, but the “( b )( 6) ” redactions likewise protect much of Jeremy Farrar’s input into these discussions.

Chris Martenson, economic researcher and post-doctorate student of neurotoxicology and founder of Peak Prosperity, has had some insightful explains on such matters, including asking why such protection has been offered to Farrar given that he is the director of a “charitable trust.” Martenson went on to question why the Wellcome Trust was involved at all in these high-level discussions.

One Fauci email, dated February 25, 2020, and sent by Amelie Rioux of the WHO, used to say that Jeremy Farrar’s official persona at that time was “to act as the board’s focal point on the COVID-1 9 outbreak, to represent and advise the board on the social sciences of the eruption and the financing of the response.”

Farrar had previously chaired the WHO’s Scientific Advisory Council. The emails too show the formulation, within a ten-day period, of the SARS-CoV-2 “‘origins” paper, which was entitled “The Proximal Origin of SARS-CoV-2” and was accepted for brochure by Nature Medicine on March 17, 2020.

The paper claimed that the SARS-CoV-2 virus could only have come from natural starts as opposed to gain-of-function research, a claim once accommodated as revelation in the mainstream but which is coming back under great investigation in recent weeks.

Shaping the presentation of an ancestry floor for a virus of world-wide important is something Farrar has been involved with before. In 2004-5, it was reported that Farrar and his Vietnamese colleague Tran Tinh Hien, the weaknes head at the Hospital for Tropical Infection, were the first to identify the re-emergence of the avian flu( H5N1) in humans.

Farrar has recounted the descent tale on many occasions, territory: “It was a boy. She caught it from a domesticated duck that had died and she’d dug up and reburied. She survived.” According to Farrar, its own experience motivated him to found a global network in conjunction with the World Health Organization to “improve neighbourhood responses to disease outbreaks.”

An article published by Rockefeller University Press’s Journal of Experimental Medicine in 2009 is dramatically named, “Jeremy Farrar: When Disaster Strikes.” Farrar, when referring to the H5N 1 cause storey territory: “The WHO people–and this is not a criticism–decided it was unlikely that the child had SARS or avian influenza.

They left, but Professor Hien stayed behind to talk with the child and her mum. The girl admitted that she had been quite sad in the previous days with the death of her domesticated duck. The girl and her friend had engaged over burying the duck and, because of this argument, she had gone back, dig up the duck, and reburied it–probably so her friend wouldn’t know where it was buried.

With that autobiography, Professor Hien phoned me at home and said he was worried about the child. He made some swabs from the child’s nose and throat and impart them back to the hospital. That night the laboratory flowed research on the tests, and they were positive for Influenza A.”

With Farrar now having been uncovered as an instrumental part of the team that crafted the official story regarding the inceptions of SARS-CoV-2, his previous assertions about the lineage of past scourges should be scrutinized.

As the director of a “charitable trust, ” Jeremy Farrar is almost completely inscrutable for its membership in crafting controversial narrations related to the COVID crisis. He continues to be at the forefront of the global response to COVID, in part by launching the Wellcome Leap Fund for “unconventional activities, funded at scale” as an overt attempt to create a world and “charitable” version of DARPA.

Indeed, Farrar, in consider Wellcome Leap, has stood himself to be just as, if not more, instrumental in building the foundation for the post-COVID era as he was in building the foundation for the COVID crisis itself.

This is significant as Wellcome Leap CEO Regina Dugan has labeled COVID-1 9 this generation’s “Sputnik moment” that will launch a new age of “health innovation, ” much like the launching of Sputnik started a world technological “space age.” Wellcome Leap perfectly intends to lead the pack.

“Rulers” of the Gene-Sequencing Industry

In contrast to the overt DARPA, Silicon Valley, and Wellcome bonds of the others, the chairman of the board of directors of Wellcome Leap, Jay Flatley, has a different background. Flatley is the long-time head of Illumina, a California-based gene-sequencing hardware and software monstrous that is believed to currently predominate the field of genomics.

Though he stepped down from the board of Illumina in 2016, he has continued to serve as the executive chairman of its board of directors. Flatley was the first to be chosen for a lead orientation at Wellcome Leap, and he was responsible for suggesting Regina Dugan for the organization’s chief operating officer, according to a recent interrogation given by Dugan.

Illumina Campus Illumina Campus. Source: Glassdoor

As a profile on Illumina in the business magazine Fast Company tones, Illumina “operates behind the scenes, selling hardware and services to companies and research academies, ” among them 23 andMe. 23 andMe’s CEO, Anne Wojcicki, the sister of YouTube CEO Susan Wojcicki and the partner of Google cofounder Sergey Brin, told Fast Company, “It’s crazy. Illumina is like the ruler of this whole universe and no one knows that.”

The report aware of the fact that 23 andMe, like most fellowships that proposal DNA sequencing and analysis to purchasers, uses machines produced by Illumina.

In 2016, Illumina propelled an “aggressive” five-year plan to “bring genomics out of research labs and into doctors’ offices.” Given the current state of things, peculiarly the global push toward gene-focused vaccines and rehabilitations, that contrive, which concludes this year, could not have been any better timed.

Illumina’s current CEO, Francis DeSouza, previously held key uprights at Microsoft and Symantec. Also in 2016, Illumina’s executive teams foreshadow a future in which humans are gene tested from birth to grave for both state and commercial purposes.

Whereas most companionships have striven financially during the coronavirus pandemic, some have appreciated a massive increase in benefits. Illumina has watched its share price double since the start of the COVID crisis.

The company’s$ 1 billion plus in earnings during the last tax year was obviously helped by the quick approval of the NovaSEQ 6000 machines, which can test a large number of COVID tests more quickly than other manoeuvres. An soul machine has a hefty price tag of nearly$ 1 million, and thus they are mostly found at elite equipment, private labs, and top-tier universities.

Jay Flatley Jay Flatley, Executive Chairman, Illumina, speaking at World Economic Forum in Davos 2018. Source: WEF

In addition to his long-standing leadership capacity at Illumina, Jay Flatley is also a “digital member” of the World Economic Forum as well as the lead independent director of Zymergen, a WEF “tech pioneer” company that is “rethinking biology and reimagining the world.”

Flatley, who has also attended various Davos congregates, has addressed the WEF on the “promise of precision[ i.e ., gene-specific] medicine.”

At another WEF panel meeting, Flatley, alongside UK Health Secretary Matt Hancock, promoted the relevant recommendations of preparing genomic sequencing of babies at birth standards and norms, claiming it had “the potential to alter the healthcare system from reactive to preventative.”

Some at the panel called for the genomic sequencing of infants to eventually become mandatory.

Aside from Flatley as an individual, Illumina as a company is a WEF partner and plays a key role in its platform regarding the future of health care. A top Illumina executive also serves on the WEF’s Global Future Council on Biotechnology.


Wellcome Leap currently has four planneds: Multi-Stage Psych, Delta Tissue, 1KD, and HOPE. HOPE was the first program to be announced by Wellcome Leap and stands for Human Organs, Physiology and Engineering. Harmonizing to the full program description, HOPE strives “to leverage the supremacy of bioengineering to advance stem cells, organoids, and whole organ the mechanisms and bonds that recapitulate human physiology in vitro and reinstate vital capacities in vivo.”

human organs physiology and engineering Source: Wellcome Leap, https :// wellcomeleap.org/ hope /

HOPE consists of two main program goals. First, it seeks to “bioengineer a multiorgan programme that recreates human immunological responses with sufficient fidelity to double the predictive price of a preclinical trial with respect to efficacy, toxicity and immunogenicity for therapeutic interventions.”

In other texts, this bioengineered scaffold mimicking human organs would be used to test the effects of pharmaceutical products, including vaccines, which could create a situation in which animal contests are replaced with inquiries on gene-edited and raised organs.

Though such an advance would certainly be helpful in the sense of reducing often unethical animal experimentation, trusting such a fiction plan to allow medical treatments to go straight to the human-testing phase would also require trusting the relevant institutions developing that system and its funders.

As it stands now, the Wellcome Trust has too many ties to demoralize actors in the pharmaceutical industry, having originally begun as the “philanthropic” arm of UK drug giant GlaxoSmithKline, for anyone to trust what they are producing without actual independent corroboration, given the histories of some of their development partners in fudging both animal and human clinical ordeal data for inoculations and other products.

The second objective of HOPE is to open up the use of machine-human hybrid organs for transplantation into human being. That purpose focuses on restoring “organ offices utilizing prepared organs or biological/ synthetic composite systems” with the later goal of bioengineering a fully transplantable human organ after several years.

Later on in the program description, nonetheless, the interest in merging the synthetic and biological becomes clearer when it districts: “The experience is right to foster synergies between organoids, bioengineering and immunoengineering engineerings, and betterment the state-of-the-art of in vitro human biology … by construct controllable, accessible and scalable systems.”

The program description document also notes the interest of Wellcome in genetic-engineering approaches for the “enhancement of desired dimensions and introduction of traceable markers” and Wellcome’s ambition to reproduce the building blocks of the human immune system and human part plans through technological means.

Transhumanist Toddlers?

The second program to be pursued by Wellcome Leap is called “The First 1000 Daylights: Promoting Healthy Brain Networks, ” which is abbreviated as 1KD by the organization. It is arguably the most unsettling program because it seeks to use young children, specifically infants from three months to three-year-old toddlers, as its test subjects.

The program is being overseen by Holly Baines, who has ever dished as programme evolution conduct for the Wellcome Trust before attaching Wellcome Leap as the 1KD planned leader.

the first 1000 days Source: Wellcome Leap, https :// wellcomeleap.org/ 1kd /

1KD focuses primarily on developing “objective, scalable ways to assess a child’s cognitive health” by monitoring the brain development and office of babes and toddlers, accepting practitioners to “risk-stratify children” and “predict responses to interventions” in developing brains.

The program description document notes that, up to this point in record, “our primary space into the developing brain has been neuroimaging skills and animal simulates, which can help identify quantitative biomarkers of[ neural] system state and characterise system divergences underlying behaviours.” It then include an indication that advances in technology “are opening additional potentials in young infants.”

The program description says that artificial neural network, a form of AI, “have demonstrated the viability of modelling network pruning process and the acquisition of complex attitudes in much the same way as a developing brain, ” while improvements in machine learning, another subset of AI, can now be used to extract “meaningful signals” from the brains of infants and young children.

These algorithms can then be used to develop “interventions” for young children regarded by other algorithms to be in danger of having underdeveloped brain function.

The document goes on to note the promise of “low-cost mobile sensors, wearables and home-based systems” in “providing a new opportunity to assess the influence and reliance of brain development on natural physical and social interactions.”

In other words, this program seeks to use “continuous visual and audio recordings in the home” as well as wearable devices on children to collect millions upon millions of data points. Wellcome Leap describes these wearables as “relatively inconspicuous, scalable electronic badges that muster visual, auditory and motion data as well as interactive pieces( such as turn-taking, speeding and reaction times ). “

Elsewhere in the document there is a call to develop “wearable sensors that assess physiological bars predictive of brain health( e.g ., electrodermal act, respiratory rate, and heart rate) and wireless wearable EEG or eye-tracking technology” for use in babies and children three and under.

Like other Wellcome Leap planneds, information and communication technologies is being developed with the intention of acquiring it mainstream in medical discipline within the next five to ten years, meaning that this system–although enclose as a way to monitor children’s brain functioning to improve cognitive outcomes–is a recipe for total surveillance of babes and very young children as well as a means for altering their brain functioning as algorithms and Leap’s programmers see fit.

1DK has two main program purposes. The first is to “develop a fully integrated model and quantitive appraisal tools of structure development in the first 1000 days[ of living ], sufficient to predict EF[ executive operate] pattern before a child’s first birthday.”

Such a representation, the specific characteristics predicts, “should predict contributions of nutrition, the microbiome and the genome” on mentality constitution as well as the effects of “sensimotor and social interactions[ or shortage thereof] on network pruning processes” and EF outcomes. The second goal makes it clear that widespread adoption of such neurological-monitoring engineerings in young children and newborns is the endgame for 1DK.

It states that the program plans to “create scalable methods for optimising promotion, prevention, screening and therapeutic interventions to improve EF by at least 20% in 80% of children before age 3. “

True to the eugenicist ties of the Wellcome Trust( to be considered more in-depth in Part 2 ), Wellcome Leap’s 1DK notes that “of interest are betterments from underdeveloped EF to normative or from normative to well-developed EF across the population to deliver the broadest impact.”

One of the goals of 1DK is thus not considering illnes or addressing a “global health populace challenge” but instead experimenting on the cognitive augmentation of children using implies developed by AI algorithms and invasive surveillance-based technology.

Another unsettling aspect of the program is its plan to “develop an in vitro 3D intelligence assembloid that mimics the time formation” of a developing brain that is akin to the poses put forward by monitoring the brain development of babes and children.

Later on, the program description calls this an “in-silico” modeling of a child’s brain, something of self-evident interest to transhumanists who participate such a development as a harbinger of the so-called singularity.

Beyond that, it appears that this in-silico and thus synthetic example of the ability is planned to be used as the “model” to which infant and children brains are shaped by the “therapeutic interventions” mentioned elsewhere in the program description.

It should be clear how sinister it is that an organization that brings together the worst “mad scientist” caprices of both the NGO and military-research worlds is openly planning to conduct such ventures on the brains of newborns and toddlers, goal them as datasets and their intelligences as something to be “pruned” by machine “intelligence.”

Allowing such a program to advance unimpeded without pushback from the public would convey granting a perilous agenda targeting society’s youngest and most vulnerable members to potentially betterment to a top where it is difficult to stop.

A “Tissue Time Machine”

The third and second-most recent program to join the Wellcome Leap lineup is called Delta Tissue, abbreviated by the organization as DT. Delta Tissue aims to create a stage that observes changes in human-tissue function and interactions in real epoch, ostensibly to “explain the status of a disease in each person and better predict how that illnes would progress.”

Referring to this platform as a “tissue time machine, ” Wellcome Leap realise Delta Tissue as being able to predict the onset of malady before it occurs while also allowing for medical involvements that “are targeted to the individual.”

delta tissue Source: Wellcome Leap, https :// wellcomeleap.org/ delta-tissue /

Well before the COVID era, precision drug or remedy “targeted or tailored to the individual” has been a code phrase for managements based on patients’ genetic data and/ or for cares that reform nucleic acid( e.g ., DNA and RNA) function itself. For instance, the US government defines “precision medicine” as “an developing coming for disease medicine and prevention that makes into account individual variability in genes, environment, and life for each person.”

Similarly, a 2018 newspaper published in Technology notes that, in oncology, “precision and personalized medicine … promotes the development of specialized managements for each specific subtype of cancer, based on the measurement and manipulation of key patient genetic and omic data( transcriptomics, metabolomics, proteomics, etc .). “

Prior to COVID-1 9 and the inoculation roll outs, the mRNA vaccine technology used by the DARP-Afunded business Moderna and Pfizer were marketed as being precision medicine medications and were largely referred to as “gene therapies” in media reports.

They were also promoted heavily as a progressive procedure of treating cancer, moving it unsurprising that the Delta Tissue planned at Wellcome Leap would use a similar justification to develop a program that aims to offer accommodated gene cares to people before the onset of a disease.

This Delta Tissue stage works to combine “the latest cell and material profiling engineerings with recent advances in machine learning, ” that is, AI.

Given Wellcome Leap’s connections to the US armed, it is worth noting that the Pentagon and Google, both onetime boss of Wellcome Leap CEO Regina Dugan and COO Ken Gabriel, have been working together since last September on using AI to predict disease in humen, first focusing on cancer before expanding to COVID-1 9 and every malady in between.

The Delta Tissue planned seemed to have referred desires, as its program description makes clear that the programme eventually aims to use its stage for a multitude of cancers and infectious diseases.

The ultimate goal of this Wellcome Leap platform is “to eradicate the obstinately challenging maladies that reason so much suffering around the world.” It plans to do this through AI algorithms, nonetheless, which are never 100 percentage accurate in their predictive clevernes, and with gene-editing managements, nearly all of which are novel and have not been well tested.

That latter point is important given that one of the main methods for gene-editing in humen, CRISPR, has been is located within numerous studies to cause substantial damage to the DNA, mar that is largely irreparable( learn here, here and here ).

It seems probable that a person placed on such a hi-tech medical treatment path will continue to need a never-ending series of gene-editing treatments and perhaps other invasive hi-tech treatments to mitigate and manage the consequences of ungainly gene splicing.

Total Surveillance to Treat “Depression”

Wellcome Leap’s most recent program, launched this very week, is called “Multi-Channel Psych: Revealing Mechanisms of Anhedonia” and is officially focused on creating “complex, biological” medications for depression.

multi channel psych Source: Wellcome Leap, https :// wellcomeleap.org/ mcpsych /

Those behind Wellcome Leap frame the problem they aim to tackle with this program as follows 😛 TAGEND

“We understand that synaptic ties-in serve as the currency of neural communication, and that strengthening or fading these linkages can facilitate learning brand-new behavioral approaches and ways and means to looking at the world.

Through studies in both animal patterns and humen, we have discovered that emotional states are encoded in complex neural network pleasure patterns, and that directly changing such blueprints via psyche stimulation can change depression. We also know that disruption of these exquisitely offset systems can lead to neuropsychiatric illness.”( emphasis added)

They add that “biologically located treatments” for hollow “are not being paired to the biology of the human beings they’re being used in, ” and, thus, medicines for hollow need to be tailored “to the specific biology” of “patients “. They be made clear that what needs to be addressed in order to make such personal modifications to treatment is to gain “easy access to the biological substrate of depression–i.e. the brain.”

Wellcome Leap’s program description notes that this effort will focus specifically on anhedonia, which it defines as “an impairment in the effort-based reward system” and as a “key symptom of recession and other neuropsychiatric illnesses.” Notably, in the fine print of the above-mentioned documents, Wellcome Leap positions 😛 TAGEND

“While there are many definitions of anhedonia, we are less interested in the investigation of shortened consummatory desire, the general experience of desire, or the inability to experience pleasure. Rather, as per the specific characteristics above, we will prioritize investigations of anhedonia as it relates to disorders in the effort-based reward system–e.g. reduced motivation to complete tasks and decreased faculty to apply effort to achieve a goal.”

In other paroles, Wellcome Leap is only interesting to treating the various aspects of depression that interfere with an individual’s work abilities , not in improving an individual’s quality or gratification of life.

Leap mentions, in discussing its goals, that it seeks to develop representations for how patients respond to treatments that include “novel or existing behavior modification, psychotherapy, drug, and neurostimulation options” while also capturing an individual’s “genome, phenome[ the sum of an individual’s phenotypic attributes ],[ neural] system connectivity, metabolome[ the sum of an individual’s metabolic characteristics ], microbiome, reinforce processing plasticity tiers, ” among others.

It eventually aims to predict the relationship between an individual’s genome to how “reward processing” purposes in the intelligence. It implies that the data used to create this pose should involve the use of wearables, stating that researchers “should seek to leverage high frequency patient-worn or in-home calculations in addition to those obtained in the clinic, hospital or laboratory.”

One of the primary study areas included in the program ogles to “develop brand-new scalable evaluation tools for reliable and high-density quantification of climate( both subjectively reported and objectively quantified via biometrics such as voice, facial expression, etc .), sleep, campaign, reward system functioning, exertion/ reason/ power degrees, social interaction, caloric uptake, and HPA axis output in real-world situations.”

The HPA( hypothalamic-pituitary-adrenal) axis is mentioned throughout the document, and this is significant as it is both a negative and positive feedback system regulating the mechanisms of stress reactions, immunity, and too birthrate in the human body.

The latter is of particular importance having regard to the Wellcome Trust’s ties to the UK eugenics action. It is likewise worth mentioning that some commercially available wearables, such as Amazon’s Halo, already quantify humor, sleep, and movement.

The program’s columnists go even further than the above in terms of what they wish to monitor in real duration, stating, “We specific encourage the development of non-invasive technology to directly ask human ability state.” Specimen include “a non-invasive spinal sound equivalent, ” “behavioral or biomarker probes of neural plasticity, ” and “single-session neural monitoring abilities that outlines a treatment-predictive mentality state.”

In other names, this Wellcome Leap platform and its columnists seek to develop “non-invasive” and, likely, wearable technology capable of monitoring an individual’s mood, facial expressions, social interactions, act and motivation, and potentially even thoughts in order to better “directly interrogate human ability state.”

To think that such a invention would stay only in the realm of research is naive, especially given that WEF dignitaries have frankly spoken at Davos engagements about how authorities plan to use such technology widely on its own population as a means of pre-emptively targeting would-be opposition and ushering in an age of “digital dictatorships.”

The focus on treating merely the aspects of depression that interfere with a person’s work further suggests that such technology, formerly developed, would be used to ensure “perfect worker” behavior in industries where human works are rapidly being replaced with AI and machines, necessitating the rulers can be more selective about which people continue to be employed and which do not.

Like other Wellcome Leap platforms, if ended, the fruits of the Multi-Channel Psych program will likely be used to ensure a population of submissive automatons whose flows and anticipates are heavily surveilled and monitored.

The Last Leap for the purposes of an Old Agenda

Wellcome Leap is no small endeavor, and its chairmen have the funding, influence, and connections to make their dreams reality. The organization’s leadership includes the key force behind Silicon Valley’s thrust to commercialize transhumanist tech( Regina Dugan ), the “architect” of the MEMS industry( Ken Gabriel ), and the “ruler” of the burgeoning genetic-sequencing industry( Jay Flatley ).

It likewise benefits from the funding of the world’s largest medical-research foundation, the Wellcome Trust, which is also one of the leading magnetisms in mold genetics and biotechnology study as well as state plan globally.

A 1994 Sunday Times investigation into the Trust noticed … … that “through[ Wellcome Trust] concessions and sponsorships, government agencies, universities, hospitals and scientists are affected all regions of the world. The rely administers more coin to academies than even the British government’s Medical Research Council.” It then mentions 😛 TAGEND

“In positions on the building’s first floor, decisions are contacted that affect lives and health on proportions similar with minor fightings. In the conference room, high-pitched above the street, and in the join residence, in the vault, verdicts in biotechnology and genetics are handed down that will help shape the human race.”

Little has changed regarding the Trust’s influence since that clause was published. If anything, its affect on investigate roads and decisions that will “shape the human race” has only grown. Its ex-DARPA officials, who have wasted their vocations advancing transhumanist engineering in both both the public and private sectors, have overlapping destinations with those off Wellcome Leap.

Dugan’s and Gabriel’s business assignments in Silicon Valley reveal that Leap presided over by those who have long sought to advance the same technology for profit and for surveillance. This drastically slackens Wellcome Leap’s claim to now be pursuing new information and communication technologies to exclusively improve “global health.”

type from your brain Regina Dugan’s Keynote at Facebook F8 2017. Source: YouTube

Indeed, as this report has shown, most of these technologies would usher in a deeply disturbing era of mass surveillance over both the external and internal activities of human beings, including young children and babies, while also creating a brand-new period of prescription located primarily on gene-editing rehabilitations, the risks of which are considerable and too consistently downplayed by its promoters.

When one understands the intimate bond that has long existed between eugenics and transhumanism, Wellcome Leap and its dreams conclude excellent impression. In a recent clause written by John Klyczek for Unlimited Hangout, it was noted that the first director general of UNESCO and former president of the UK Eugenics Society was Julian Huxley, who coined the call “transhumanism” in his 1957 record New Bottles for New Wine.

As Klyczek wrote, Huxley argued that “the eugenic goals of biologically engineering human evolution should be refined through transhumanist engineerings, which mix the eugenic methods of genetic engineering with neurotech that melts humans and machines into a brand-new organism.”

Earlier, in 1946, Huxley noted in his seeing for UNESCO that it was essential that “the eugenic problem is examined with the greatest care and that the public mind is informed of the issues at stake so that much that is now unbelievable may at least become thinkable, ” an stupefying affirmation to prepare so soon after the end of World War II.

Thanks in massive component to the Wellcome Trust and its influence on both program and medical research over the course of various decades, Huxley’s dream of rehabilitating eugenics-infused science in the post-World War II era could soon become reality. Unsurprisingly, the Wellcome Trust hosts the archive of the formerly Huxley-led Eugenics Society and still boasts close ties to its successor organization, the Galton Institute.

The over-riding question is: Will we admit ourselves continued to provide influenced into allowing transhumanism and eugenics to be openly sought and normalized, including through initiatives like those of Wellcome Leap that seek to use babies and toddlers as test subjects to advance their ghastly eyesight for humanity?

If well-crafted advertising mottoes and media campaigns painting imaginations of utopia such as “a world without disease” are all that is needed to convince us to give up our future and our children’s future to military spies, corporate execs, and eugenicists, then there is little left of our humanity to surrender.

Read more: articles.mercola.com